193 related articles for article (PubMed ID: 34794989)
1. Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study.
Connor MJ; Genie MG; Gonzalez M; Sarwar N; Thippu Jayaprakash K; Horan G; Hosking-Jervis F; Klimowska-Nassar N; Sukumar J; Pokrovska T; Basak D; Robinson A; Beresford M; Rai B; Mangar S; Khoo V; Dudderidge T; Falconer A; Winkler M; Watson V; Ahmed HU
BMJ Open; 2021 Nov; 11(11):e048996. PubMed ID: 34794989
[TBL] [Abstract][Full Text] [Related]
2. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
[TBL] [Abstract][Full Text] [Related]
3. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
4. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
6. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
7. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
10. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
13. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.
Connor MJ; Genie MG; Burns D; Bass EJ; Gonzalez M; Sarwar N; Falconer A; Mangar S; Dudderidge T; Khoo V; Winkler M; Ahmed HU; Watson V
Eur Urol Open Sci; 2022 Feb; 36():9-18. PubMed ID: 34977691
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive treatment strategies for de novo metastatic prostate cancer.
Connor MJ; Shah TT; Horan G; Bevan CL; Winkler M; Ahmed HU
Nat Rev Clin Oncol; 2020 Mar; 17(3):168-182. PubMed ID: 31712648
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
17. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
[TBL] [Abstract][Full Text] [Related]
18. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.
Newton RU; Kenfield SA; Hart NH; Chan JM; Courneya KS; Catto J; Finn SP; Greenwood R; Hughes DC; Mucci L; Plymate SR; Praet SFE; Guinan EM; Van Blarigan EL; Casey O; Buzza M; Gledhill S; Zhang L; Galvão DA; Ryan CJ; Saad F
BMJ Open; 2018 May; 8(5):e022899. PubMed ID: 29764892
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]